Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2021 Feb 2;11:621757. doi: 10.3389/fimmu.2020.621757

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

Copyright © 2021 Chen, Cao, Li, Zhao, Chen, Lai, Muend, Nossa, Wang, Guo, Ye, Lee and Feng

This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

PMC Copyright notice

Cell surface proteome analysis revealed CD71 as a potential target for synthetic PrCR upon V-ATPase inhibition. (A) Examination of cell surface marker expression on SW620 cells treated with vehicles or concanamycin with an antibody array containing a panel of 332 antibodies. (B) Identification of 15 upregulated and 3 downregulated surface proteins upon concanamycin treatment. (C) Representative flow cytometry staining of the upregulated and downregulated surface proteins on SW620 upon concanamycin treatment. (D, E) Flow cytometry analyses showing the upregulation CD71 expression on the cell surface of concanamycin-treated SW620 (D) or MDA-MB-231 (E) cells. (F, G) Phagocytosis assay with BMDMs showing that concanamycin treatment enabled macrophage-mediated PrCR of SW620 (F) or MDA-MB-231 (G) cells induced by CD71 antibodies. Each group was compared with corresponding Ctrl group. **P < 0.01 (t test).